PF-Atlas › Drugs › NAD

NAD

Idiopathic Pulmonary Fibrosis · Restores NAD+ levels depleted in aging lungs — supports sirtuin-mediated DNA repair and mitochondrial function

Mechanism
Restores NAD+ levels depleted in aging lungs — supports sirtuin-mediated DNA repair and mitochondrial function
Development stage
Phase I/II
Evidence level
Level 3 (Phase I)
Developer
Multiple

Overview

NAD+ declines with age and in IPF lung tissue. NMN/NR supplementation restores levels. Supports SIRT1/3 activity protecting against fibrosis. Low risk, available as supplement. Multiple aging clinical trials ongoing.

Explore related

Treatment profileRestores NAD+ levels depleted in aging lungs — supports sirtuin-mediated DNA repair and mitochondrial functionAll trialsResearch
Medical disclaimer. This page summarizes research about NAD for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.